abcam

ab250529

Anti-RAP1A + RAP1B antibody [EPR14815(B)] - BSA and Azide free

Recombinant | RabMAb

Key facts

Isotype	IgG
Host species	Rabbit
Storage buffer	pH: 7.2 - 7.4 Constituents: PBS
Form	Liquid
Clonality	Monoclonal
Immunogen	The exact immunogen used to generate this antibody is proprietary information.
Carrier free	Yes
Clone number	EPR14815(B)
Purification technique	Affinity purification
Concentration	1.033 mg/mL The concentration of this product may be batch-dependent Batch concentration finder →

Reactivity data

IP

Tested

Species	Human
Dilution info	-

Notes	-

Predicted

Species	Mouse, Rat
Dilution info	-
Notes	-

WB

Tested

Species	Human
Dilution info	-
Notes	-

Predicted

Species	Mouse, Rat
Dilution info	-
Notes	-

Flow Cyt (Intra)

Tested

Species	Human
Dilution info	-
Notes	-

Predicted

Species	Mouse, Rat
Dilution info	-
Notes	-

Target data

See full target information RAP1A

Function	Counteracts the mitogenic function of Ras, at least partly because it can interact with Ras GAPs and RAF in a competitive manner. Together with ITGB1BP1, regulates KRIT1 localization to microtubules and membranes (PubMed:17916086). Plays a role in nerve growth factor (NGF)-induced neurite outgrowth. Plays a role in the regulation of embryonic blood vessel formation. Involved in the establishment of basal endothelial barrier function. Facilitates the progressive accumulation of CDH1 at mature desmosome junctions via cAMP-dependent signaling and its interaction with PKP3 (PubMed:25208567). May be involved in the regulation of the vascular endothelial growth factor receptor KDR expression at endothelial cell-cell junctions.

Storage

Shipped at conditions	Blue Ice
Appropriate short-term storage conditions	+4°C
Appropriate long-term storage conditions	+4°C
Storage information	Do Not Freeze

Notes

ab250529 is the carrier-free version of ab181858.

Patented technology

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?

This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

Conjugation ready

Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.

Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.

Product promise

Tested

We have tested this species and application combination and it works. It is covered by our product promise.

Expected

We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.

Predicted

This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.

Not recommended


We do not recommend this combination. It is not covered by our product promise.

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.


3 product images



Flow Cytometry (Intracellular) - Anti-RAP1A + RAP1B antibody [EPR14815(B)] - BSA and Azide free (ab250529)

RAP1A + RAP1B Flow Cytometry (Intracellular) staining using rabbit Anti-RAP1A + RAP1B antibody

This data was developed using ab181858, the same antibody clone in a different buffer formulation.
Intracellular Flow Cytometry analysis of paraformaldehyde-fixed HeLa cells labeling RAP1B with ab181858 at a 1/30 dilution and secondary antibody goat anti-rabbit IgG (FITC, red) at a 1/150 dilution, or negative control rabbit IgG (green).



Immunoprecipitation - Anti-RAP1A + RAP1B antibody [EPR14815(B)] - BSA and Azide free (ab250529)


This data was developed using ab181858, the same antibody clone in a different buffer formulation.
Western blot analysis on immunoprecipitation from 1) 293 cell lysate or 2) negative control, labeling RAP1B using ab181858 at 1/50 dilution and HRP-conjugated anti-rabbit IgG preferentially detecting the non-reduced form of rabbit IgG at a 1/1500 dilution.

All lanes:
Immunoprecipitation - Anti-RAP1A + RAP1B antibody [EPR14815(B)] (ab181858)

Developed using the ECL technique.

Predicted band size: 21 kDa

Observed band size: 21 kDa



Western blot - Anti-RAP1A + RAP1B antibody [EPR14815(B)] - BSA and Azide free (ab250529)

RAP1A + RAP1B Western blot staining using rabbit Anti-RAP1A + RAP1B antibody

This data was developed using ab181858, the same antibody clone in a different buffer formulation.
All lanes:
Western blot - Anti-RAP1A + RAP1B antibody [EPR14815(B)] (ab181858) at 1/50000 dilution

Lane 1:
Hela cell lysate at 20 µg

Lane 2:
A431 cell lysate at 20 µg

Lane 3:
293 cell lysate at 20 µg

Lane 4:
MOLT4 cell lysate at 20 µg

Secondary

All lanes:
goat anti-rabbit IgG, (H+L), peroxidase conjugated at 1/1000 dilution

Developed using the ECL technique.

Predicted band size: 21 kDa

Observed band size: 21 kDa

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.